BOSTON--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of precision immunotherapies for treatment of patients with solid tumors, ...
The IPO window is starting to crack open and Affini-T Therapeutics plans to push through in 2024. The financial plans relayed by CEO Jak Knowles in an interview with Fierce Biotech occur as the ...
Cell therapy gives oncologists a powerful cancer-fighting tool, but these treatments made by engineering immune cells still have limitations. For one, their abilities in blood cancers fall short in ...
BOSTON & SEATTLE--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data for its lead ...
BOSTON & SEATTLE & EMERYVILLE, Calif.--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, and Metagenomi, Inc., a ...
From left: Affini-T scientific co-founders and Fred Hutch investigators Philip Greenberg, Aude Chapuis, and Thomas Schmitt. (Fred Hutch Photos) New funding: Affini-T Therapeutics, a cell therapy ...
Affini-T Therapeutics has raised $175 million to develop new cancer treatments. The cell therapy startup is hoping to fight solid tumors with edited human immune cells. Insider got the 24-page pitch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results